Core Insights - MediWound Ltd. reported a first-quarter revenue of $4 million for 2025, reaffirming full-year revenue guidance at $24 million [1][6] - The VALUE Phase III trial for EscharEx is progressing as planned, with recruitment underway for 216 patients across 40 clinical sites [5][2] - NexoBrid's revenue saw a significant increase, with Vericel reporting a 207% year-over-year growth for the first quarter of 2025 [4][2] Financial Performance - Total revenue for Q1 2025 was $3.955 million, down from $4.964 million in Q1 2024 [24] - Gross profit for the quarter was $738,000, resulting in a gross margin of 19%, compared to $607,000 and 12% in the prior year [24] - Operating loss for Q1 2025 was $5.225 million, compared to a loss of $3.734 million in Q1 2024 [24] Clinical Developments - The VALUE Phase III study for EscharEx is designed to enroll 216 patients, with most U.S. sites already open and European sites expected to activate in Q3 2025 [5][2] - A head-to-head Phase II study comparing EscharEx to collagenase has been submitted to the FDA, expected to start in the second half of 2025 [5][2] - EscharEx demonstrated superior efficacy in a post hoc analysis compared to collagenase ointment, achieving faster debridement and improved wound closure outcomes [5][6] Strategic Collaborations - MediWound has established strategic research collaborations with leading wound care companies, enhancing the validation of EscharEx [5][2] - Kerecis will provide its MariGen Fish-Skin graft for the diabetic foot ulcers trial, marking a significant collaboration [5][2] Manufacturing and Operational Updates - The company is on track with the expansion of NexoBrid manufacturing, expecting full operational capacity by the end of 2025 [1][2] - A BARDA-funded planning process for future U.S.-based manufacturing capabilities is underway [11][2] Balance Sheet Highlights - As of March 31, 2025, cash and cash equivalents totaled $38.7 million, down from $43.6 million at the end of 2024 [7] - The company used $5.1 million to fund operations during Q1 2025 [7]

Core Viewpoint - NIO Inc. will report its unaudited financial results for Q1 2025 on June 3, 2025, before U.S. market opens [1] Financial Reporting - The earnings conference call will take place at 8:00 AM U.S. Eastern Time on June 3, 2025 [2] - A live and archived webcast of the conference call will be available on the Company's investor relations website [2] Participation Details - Participants wishing to join the conference call must register in advance and dial in 10 minutes prior to the call [3] - Replay of the conference call will be accessible by phone until June 10, 2025, with specific dial-in numbers provided for various regions [3] Company Overview - NIO Inc. is a leading company in the global smart electric vehicle market, founded in November 2014 [4] - The Company aims to shape a sustainable future with the mission of "Blue Sky Coming" and focuses on innovative technology and user experience [4] - NIO offers premium smart electric vehicles under its brand, family-oriented vehicles through the ONVO brand, and high-end electric cars with the FIREFLY brand [4]

CALGARY, Alberta, May 20, 2025 (GLOBE NEWSWIRE) -- Helium Evolution Incorporated (TSXV:HEVI) ("HEVI" or the "Company"), a Canadian-based helium exploration company focused on developing assets in southern Saskatchewan, today announced the filing of the Company’s interim condensed financial statements and associated management’s discussion and analysis for the three months ended March 31, 2025 (the “Q1 Report”). Complete details of the Q1 Report are available on SEDAR+ at www.sedarplus.ca, and on HEVI’s webs ...

Company now exclusively focused on the growing fertility market following the April 2025 announcement to divest a majority stake in Naya TherapeuticsSARASOTA, Fla., May 20, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) (“INVO Fertility” or the “Company”), a healthcare services fertility company focused on expanding access to advanced treatment through the establishment, acquisition and operation of fertility clinics and related businesses and technologies, today announced first quarter 2025 fi ...

Company Overview - Imperial Petroleum Inc. is a ship-owning company that provides petroleum products, crude oil, and drybulk seaborne transportation services [4] - The company owns a total of thirteen vessels, including seven M.R. product tankers, two suezmax tankers, three handysize drybulk carriers, and one panamax drybulk carrier, with a total capacity of 807,000 deadweight tons (dwt) [4] - Imperial Petroleum has contracted to acquire an additional six drybulk carriers with an aggregate capacity of 387,000 dwt, which will increase the fleet to a total of 19 vessels [4] - The company's shares are listed on the Nasdaq Capital Market under the symbols "IMPP" for common stock and "IMPPP" for 8.75% Series A Cumulative Redeemable Perpetual Preferred Stock [4] Upcoming Financial Results - The company will release its first quarter financial results for the period ended March 31, 2025, before the market opens in New York on May 23, 2025 [1] - A conference call will be hosted by the company's management on May 23, 2025, at 10:00 am ET to discuss the results and the company's operations and outlook [1]

HARRISBURG, Pa., May 20, 2025 (GLOBE NEWSWIRE) -- Ollie's Bargain Outlet Holdings, Inc. (NASDAQ: OLLI) (the "Company") today announced that it will report its financial results for the first quarter fiscal 2025 before the market opens on Tuesday, June 3, 2025. Eric van der Valk, President and Chief Executive Officer, and Robert Helm, Executive Vice President and Chief Financial Officer, will host a conference call with the investment community to discuss the financial results and answer questions at 8:30 a. ...

Investor Presentation - Financial Results Q1 2025 Attachments Q1 2025 Investor Presentation Q1 2025 Investor Presentation ...

Total revenues of US$82.8 million exceeded guidance, up 135.9% YoYBitcoin mining revenues reached US$24.3 million, up 131.9% YoYSINGAPORE, May 20, 2025 /PRNewswire/ -- Canaan Inc. (NASDAQ: CAN) ("Canaan" or the "Company"), an innovator in crypto mining, today announced its unaudited financial results for the three months ended March 31, 2025.First Quarter 2025 Operating and Financial HighlightsTotal revenues were US$82.8 million, which beat the guidance of US$75 million and increased 135.9% year-over-year.T ...

Core Insights - Trip.com Group Limited reported strong growth in its international businesses, with overall reservations on its international OTA platform increasing by over 60% year-over-year and inbound travel bookings surging by around 100% year-over-year [2][3] - The company achieved net revenue of RMB13.8 billion (US$1.9 billion) for the first quarter of 2025, representing a 16% increase from the same period in 2024, driven by stronger travel demand [4] - The travel industry maintained strong momentum in the first quarter of 2025, supported by resilient consumer demand and favorable travel policies [3] Financial Performance - Accommodation reservation revenue for Q1 2025 was RMB5.5 billion (US$764 million), a 23% increase from Q1 2024 [5] - Transportation ticketing revenue for Q1 2025 was RMB5.4 billion (US$747 million), an 8% increase from Q1 2024 [6] - Packaged-tour revenue for Q1 2025 was RMB947 million (US$131 million), a 7% increase from Q1 2024 [7] - Corporate travel revenue for Q1 2025 was RMB573 million (US$79 million), a 12% increase from Q1 2024 [8] - Net income for Q1 2025 was RMB4.3 billion (US$596 million), unchanged from Q1 2024 [14][15] Cost Structure - Cost of revenue for Q1 2025 increased by 21% to RMB2.7 billion (US$373 million) compared to Q1 2024 [9] - Product development expenses for Q1 2025 increased by 13% to RMB3.5 billion (US$486 million) from Q1 2024 [10] - Sales and marketing expenses for Q1 2025 increased by 30% to RMB3.0 billion (US$413 million) from Q1 2024 [11] - General and administrative expenses for Q1 2025 increased by 11% to RMB1.0 billion (US$143 million) from Q1 2024 [12] Cash Position and Shareholder Returns - As of March 31, 2025, the company had cash and cash equivalents totaling RMB92.9 billion (US$12.8 billion) [17] - The company repurchased 1.6 million ADSs for a total gross consideration of US$84 million as part of its share repurchase plan [18]

Merger Negotiations - Eyenovia is in ongoing negotiations for a binding merger agreement with Betaliq, a clinical-stage pharmaceutical company focused on glaucoma [2] - The exclusivity period for the merger discussions has been extended until June 7, 2025, to facilitate the completion of the agreement [2] Optejet Development - The development of the Optejet user-filled device (UFD) is progressing well, with plans to file for U.S. regulatory approval in September 2025 [3] - Approval of the Optejet could lead to multiple commercial opportunities, both directly with consumers and through partnerships with eye care practitioners and license partners [3] Financial Performance - For Q1 2025, Eyenovia reported a net loss of $3.5 million, or $1.59 per share, a significant improvement from a net loss of $10.9 million, or $18.75 per share, in Q1 2024 [6][16] - Research and development expenses decreased by 85% to $0.7 million in Q1 2025, compared to $4.4 million in Q1 2024 [6] - General and administrative expenses were reduced by 35% to $2.4 million in Q1 2025, down from $3.6 million in Q1 2024 [7] - Total operating expenses for Q1 2025 were $3.0 million, a decrease of 70% from $10.1 million in Q1 2024 [7] Cash Position - As of March 31, 2025, the company's unrestricted cash and cash equivalents were $3.9 million, an increase from $2.1 million at the end of 2024 [7][14] - A debt restructuring agreement was entered into earlier this year, deferring certain repayment obligations until October 2025, which has contributed to extending the company's cash runway [4][5]